Table 1

Patient characteristics

Visits with MIVisits without MI
Number of visits2686 (9.7)25 123 (90)
Age (years), median (IQR)76 (66–84)71 (60–81)
Women1073 (40)10 999 (44)
Comorbidities
 Prior MI1213 (45)6411 (26)
 Prior revascularisation1059 (39)6719 (27)
 Prior stroke419 (16)3022 (12)
 Heart failure7968 (32)957 (36)
 Diabetes890 (33)6407 (26)
 Hypertension2020 (75)16 693 (66)
 Atrial fibrillation731 (27)8095 (32)
 Dialysis77 (2.9)321 (1.3)
 COPD382 (14)3839 (15)
Laboratory data
 First hs-cTnT concentration (ng/L), median (IQR)55 (27–161)14 (8–26)
 Historical hs-cTnT concentration, (ng/L), median (IQR)16 (9–33)9 (5–18)
 Relative change between historical and first hs-cTnT concentration, median (IQR)166% (52–602)29% (14–63)
 Haemoglobin (g/L), median (IQR)132 (119–145)135 (123–146)
 Nt-pro-BNP (ng/L), median (IQR)2480 (664–6593)1020 (280–3334)
eGFR (mL/min/1.73 m2):
 >601510 (56)17 113 (68)
 30–59882 (12)6574 (26)
 <30292 (11)1439 (5.7)
Medications
 Aspirin1507 (56)10 374 (41)
 P2Y12 inhibitors*460 (17)2850 (11)
 Any platelet inhibitor†1653 (62)11 585 (46)
 Beta-blockers1686 (63)14 391 (57)
 ACEi/ARB1497 (56)12 719 (51)
 Statins1336 (50)10 563 (42)
 DOAC76 (2.8)1018 (4.1)
 OAC‡386 (14)4891 (19)
 Warfarin317 (12)3961 (16)
Mortality within 30 days
 All-cause mortality163 (6.1)424 (1.7)
 Cardiovascular mortality126 (4.7)214 (0.9)
 Non-cardiovascular mortality37 (1.4)210 (0.8)
  • Data are presented as n (%), or median with IQR.

  • *Includes treatment with clopidogrel, ticagrelor, dipyradimole or prasugel.

  • †Includes treatment with aspirin or P2Y12 inhibitors.

  • ‡Includes treatment with NOAC or warfarin.

  • ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; DOAC, direct oral anticoagulants; eGFR, estimated glomerular filtration rate; hs-cTnT, high-sensitivity cardiac troponin T; MI, myocardial infarction; Nt-pro-BNP, N-terminal pro b-type natriuretic peptide; OAC, oral anticoagulants.